Metallocenes as target specific drugs for cancer treatment

The application use of organometallic compounds into the cancer research was established in the late 1970s by Köpf-Maeir and Köpf. This new research area has been developed for the past 30 years. In the early 1980s, Jaouen and coworkers recognized the potential application of organometallic compounds vectorized with pendant groups that can deliver the drug to certain specific receptors. This is what is called nowadays target specific drugs. This review will focus on metallocenes vectorized with steroids derivatives of hormones, nonsteroidal and selective endocrine modulator.